Compare · DRIO vs RMD
DRIO vs RMD
Side-by-side comparison of DarioHealth Corp. (DRIO) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRIO and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $28.86B, about 579.3x DRIO ($49.8M).
- Over the past year, DRIO is down 51.8% and RMD is down 22.9% - RMD leads by 29.0 points.
- Both names hit the wire about 7 times in the past 4 weeks.
- RMD has more recent analyst coverage (25 ratings vs 4 for DRIO).
- Company
- DarioHealth Corp.
- ResMed Inc.
- Price
- $6.67-7.81%
- $198.99-1.86%
- Market cap
- $49.8M
- $28.86B
- 1M return
- -6.39%
- +2.60%
- 1Y return
- -51.84%
- -22.85%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 7
- 7
- Recent ratings
- 4
- 25
DarioHealth Corp.
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario Tools, which are devices that integrate with applications on a user's smartphone; DarioEngage, a population health management platform; and the Dario Loop, an AI-driven journey engine. It also sells device-specific disposables test strip cartridges, lancets, and Dario Blood Glucose Monitoring System; and Dario Smart Diabetes Management Solution, which includes tools to help diabetic patients manage their disease. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is based in New York, New York.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest DRIO
- Fortune 50 Employer Awards Dario Contract to Deliver AI-Powered Cardiometabolic Care Platform
- Dario Expects Proprietary AI Engine DarioIQ™ to Increase Recurring Revenue from Existing Customers by 10-15%
- DarioHealth Corp. filed SEC Form 8-K: Leadership Update
- Dario Signs New Agreement with a Major Health Insurer in Arizona Representing Hundreds of Thousands of Lives Through Amwell Partnership
- Top National Health Plan Extends Agreement for Mental Health and Expands Dario Partnership into Cardiometabolic Care, Demonstrating Successful Multi-Condition Growth Strategy
- Dario Appoints Former Humana Chief Compliance Officer Sean O'Reilly to Advisory Board to Support Strategic Growth and Healthcare Partnerships
- Dario Announces Strategic Collaboration with Beluga Health to Deliver Provider-Backed, Integrated Care at Scale
- Dario Presents Four Studies at American Diabetes Association Scientific Sessions Highlighting Commercial and Clinical Value of its Digital Health Platform
- Dario More Than Doubles Addressable Market in Solera Health's Network via Expanded Hypertension Program, With Dario Now Reaching Greater Than 500,000 Eligible Lives
- DarioHealth Reports First Quarter 2026 Financial and Operating Results
Latest RMD
- ResMed downgraded by RBC Capital Mkts with a new price target
- ResMed downgraded by Citigroup with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,090,771 worth of ResMed Common Stock (4,991 units at $218.55) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure
- Resmed Announces Agreement to Sell MatrixCare Business
- SEC Form 144 filed by ResMed Inc.
- Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
- ResMed downgraded by Morgan Stanley with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $968,064 worth of ResMed Common Stock (4,991 units at $193.96) as part of a pre-agreed trading plan, increasing direct ownership by 0.01% to 466,256 units (SEC Form 4)
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)